CN1822880A - Parasiticidal composition - Google Patents
Parasiticidal composition Download PDFInfo
- Publication number
- CN1822880A CN1822880A CNA200480020006XA CN200480020006A CN1822880A CN 1822880 A CN1822880 A CN 1822880A CN A200480020006X A CNA200480020006X A CN A200480020006XA CN 200480020006 A CN200480020006 A CN 200480020006A CN 1822880 A CN1822880 A CN 1822880A
- Authority
- CN
- China
- Prior art keywords
- compositions according
- drug
- closantel
- supplying system
- alcohols
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/36—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids
- A01N37/38—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids having at least one oxygen or sulfur atom attached to an aromatic ring system
- A01N37/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids having at least one oxygen or sulfur atom attached to an aromatic ring system having at least one carboxylic group or a thio analogue, or a derivative thereof, and one oxygen or sulfur atom attached to the same aromatic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/609—Amides, e.g. salicylamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
Abstract
An anti-parasitic pour-on composition for treating animals comprises a salicylanilide, especially closantel, alone or together with at least one other anti-parasitic compound of the avermectin or milbemycin type and offers enhanced bioavailability of the salicylanilide by provision of a delivery system comprising at least 20%(v/v) of one or more alcohols. The composition optionally includes a polymeric moiety selected from polyvinylpyrrolidone (PVP), polyoxypropylene/polyoxyethylene block copolymers (poloxamer), and polyethylene glycols (PEG), thereby improving the bioavailability of e.g. closantel (as assessed with respect to blood plasma levels of closantel).
Description
Technical field
The present invention relates to a kind of parasitic compositions of killing, especially use compound products based on salicylamide with the another kind of veterinary who kills the parasite agent combination, as the avilamycin (avermectin) or the arteries and veins heart (Milbemycin) doubly, single to kill parasite reagent more effective than using separately to the parasitic effectiveness of wide spectrum for this compound products.
Background technology
Homoiothermic animal is subjected to parasitic biting easily, and people struggle the parasite of seeking with these torment domestic pets, farm animals and wild animals for a long time, to alleviate suffering and the acquisition trade benefit that parasite is brought.Parasitic bite mode with and life cycle in the identification of sensitive stage, the selection of parasite agent for killing is all had very big influence.Therefore, the outer processing mode of the typical skin of ectoparasite is normally adopted washing liquid, application, cream, colloid, interleaving agent, suspension (pour-ons) or disinfectant; But for tackling endoparasite, then need carefully select the method for dispenser and drug delivery for use, oral liquid medicine, sticking group, pill, tablet and food grain thing etc. all are known animal application methods, but the insecticide-applying way of other injection medicine preparation is also adopted by the insider.These alternate manners comprise the employing aerosol, in advance with parenteral medicine (injecting drug use) compositions of solution, suspension or micropowder agent preparation, subcutaneous according to desired drug delivery mode being used for of using, Intradermal or intramuscular injection.This several method of back need give special heed to preparation, to avoid causing injection place inflammation, disadvantageous anaphylaxis or exothermic reaction.
Preparation is normally with the preparation of the carrier fashion of water preparation or nonaqueous solvent (solvent).The nonaqueous solvent carrier fashion can comprise physiological ethanol, ethylene glycol or esters, the organic aromatic solvent of part, vegetable oil and extract or its modifier etc.When selecting carrier, the technical staff need consider dissolubility, medicine and the specific support of a series of problems such as the active component that is intended to use affinity, whether can have influence on other basic ilities, pH value, temporal stability, viscosity and to the toxic and side effects of being treated animal etc.In the dosage form of suspension, active component or component are entered into the convenience that takes that blood system provides effective dose by skin, be a fundamental characteristics of said composition.Therefore, the dosage form of anthelmintic is the task of a complexity.
Traditional anthelmintic comprises chemical reagent such as benzimidazole, carbaminate, and plant extract such as pyrethroid, and they are used to tackle ectoparasite such as flat louse and demodicid mite class.
Salicylamide, tendency is used to tackle the invasion and attack of fungus, and its chemically modified derivative closantel (closantel) is a kind of effective wriggling agent (worming agent).Closantel is recorded in U.S. Pat 4 005 218 and the document, as J.Guerrero et al, J.Parasitol.68,616, (1983); H.Van den Bossche et al, Arch.Int.Physiol.Biochim, 87,851 (1979); H.J.Kane et al, Mol.Biochem.Parasitol.1,347 (1980).
The normally oral absorption of closantel, as pill, oral liquid medicine, or injection medicine preparation.Mention among the open WO 95/05812 of international patent application, contain the injection anthelmintic composition of Ah going out spit of fland (neat pier demodicid mite is to plain, Abamectin) and closantel can the spent glycol based solvent such as PEG400 or propylene glycol make by glycerol formal (Glycerol Formal).Yet because local dispenser is usually than other insecticide-applying way slow (injection or oral), skin is also just very slow to the absorption of closantel, thereby the content of closantel in blood will be lower than adopting insecticide-applying way.
Closantel is that be difficult for very much being dissolved in water and very fast and combine with plasma proteins fully simultaneously, and this also illustrates that to those skilled in the art this local insecticide-applying way will reduce effective plasma concentration.
Thereby, still not have at present suitable closantel with the mixed commercial formulation of selecting the dispenser of liquid formulation form.
Avilamycin is a kind of very effective antiparasitic, is used to tackle broad-spectrum mammal endoparasite and ectoparasite, and is used in the multiple parasite that tackles on the agricultural in crop and the soil.Basic avilamycin chemical compound is from soil microorganism--and separate Avid kyowamycin (Streptomyces avermitilis) fermentation liquid, this chemical compound is recorded in the U.S. Pat 4 310 519.In addition, the derivant of these basic avilamycin chemical compounds can be by the preparation of number of chemical method.
Some avilamycin chemical compound colony comprises 22, the two keys of 23-, other on the 13-position, contain disaccharide by α-L-oleandrosyl-α-the L-oleandrosyl group is formed.As described in U.S. Pat 4 206 205, one or two unit in the saccharide all can be removed and form monosaccharide or aglycone.Aglycone has a hydroxyl on the 13-position, this hydroxyl can be removed and form the deoxy compound of 13-position, as described in U.S. Pat 4 171 314 and US 4 173 571.The acyl groupization of hydroxyl can be reached according to the description of U.S. Pat 4 201 861 in avilamycin chemical compound and the derivant thereof.
Being disclosed in a times arteries and veins in the U.S. Pat 3 950 360, to feel concerned about the row chemical compound structurally close with avilamycin family, and they all contain 16th National Congress of Communist Party of China ring circulus.But doubly arteries and veins is felt concerned about the system chemical compound and is not contained the disaccharide subunit, substituent group also with the having any different of avilamycin family.
Being recorded in the ivermectin (lvermectin) of U.S. Pat 4 199 569, is by to 22 of avilamycin chemical compound, and the two keys of 23-carry out that selective reduction prepares.Ivermectin is 22, the mixture that two hydrogen atom avilamycin B1 a of 23-and B1 b form at least 80: 20 ratio.
Ivermectin is particularly preferred active component in the Pesticidal compound, existing lot of documents put down in writing its activity, its in the body and verminal effectiveness with and to the interference characteristic of specific parasitic life cycle.Merck index (The Merck Index) (1996) has been quoted many pieces of lists of references, comprises J.C.Chabala et al, J.Med.Chem.23,1134 (1980); J.R.Egerton et al, Brit.Vet.J.136,88 (1980); W C.Campbell et al, Science 221,823-828 (1983).
Be the purpose that takes under the multiple situation, the ivermectin preparation that make oral liquid medicine, suspension, injection medicine preparation, makes an addition to particulate matter in the food and injectable paste form has been proved has very high challenge, and uses existing a large amount of patent with regard to it and come forth.Ivermectin has the lipotropy feature, but also can dissolve in aqueous solution.The dicyandiamide solution that the Yi Wei bacteria preparation is used has also given record in many patents.Visible at least EP 0 045 655 of reference material and EP 0 146 414.
Although ivermectin has wonderful effect and has obtained permanent commerce achievement, but kill parasitic scope and overcome because of some parasite has Drug resistance and needs on the defective of the increasing medicament amount of taking enlarging ivermectin, people still have very big interest.Considering that ivermectin is widely used in protection and treats those is used to the mankind to provide on the animal body of consumption by being butchered, and the residual total amount of ivermectin active component is had enforceable constraint as the residual total amount of the intravital ivermectin active component of the poultry after butchering.Therefore, even if feasible technically, the high useful load of ivermectin in drug-supplying system is not best solution.
For prolonging the use of traditional parasite agent for killing, combination formulations has been considered the Drug resistance and the drug resistance day after tomorrow of insect.This phenomenon also has fully to be proved, as, about wriggling compositions (wormingcompositions).In the above-mentioned Drug resistance problem of antagonism, associating parasite agent for killing is observed to have cooperative effect and supplies effect.Synergic insect repellent compositions is existing the discussion in the open WO94/28887 of international patent application, wherein is conceived to the succedaneum of single phenol and bis-phenol, salicylamide, benzsulfamide, halogenation benzimidazole, benzimidazole and benzimidazole carbaminate.
Avilamycin and other parasite agent for killing being united the chance of use is also probed into.A kind of combination formulations is wherein mentioned in the open WO 0061068 of international patent application: the absorbable suspension formulations of skin, it contains triclabendazole (triclabendazole), and optionally contains avilamycin, tetramisole (tetramisole) or left-handed (four) imidazoles (levamisole).Also mention a kind of injectable preparation among the open WO95/05812 of international patent application, it contains closantel and avilamycin or the arteries and veins heart doubly.Mentioned the preparation of suspension type and injectable type among the open WO 01/60380 of international patent application, wherein comprise adopt ketopyrrolidine solvent and bridge joint solvent (bridging solvent) as propylene glycol sad and ester or Oleum Arachidis hypogaeae semen.This specific difficult point mark location of dicyandiamide solution in setting forth different parasite agent for killing--as closantel and ivermectin--is essential.The effectiveness of these preparations does not obtain open.
The suspension formulations of other non-water is documented among the open WO 97/13508 of international monopoly: adopt a series of solvents, particularly polyhydric alcohol and ether thereof and their mixture, optionally combine with multiple cosolvent.The document is also announced the result of the test that reagent is provided simultaneously, and described in the comparative example of back, these reagent show limited achievement in the blood system that active component is transported to the animal of being treated.
The salicylamide derivant as closantel, can effectively be controlled a series of parasites and effective especially to Liver fluke.In the avilamycin group of anti-parasitic chemical compound, ivermectin is the most known example, and it provides the protection that replenishes for tackling many other parasites such as ascarid.Therefore, if these medicines are joined together also can just will bring benefit for controlling parasitic the infection effectively expediently to the domestic animal dispenser with certain form.
Especially, providing a kind of one of effective suspension formulations that includes closantel and ivermectin is the target that very is worth reaching.The preparation that a kind of satisfaction is provided is inconvenient, because each medicine has different dissolution system.Basic solvent provides suitable pH environment for closantel, and ivermectin then need could effectively dissolve in acid medium.
Summary of the invention
An object of the present invention is to provide a kind of veterinary medicament preparation method of improvement, particularly the object of the present invention is to provide a kind of in the body widely and ectoparsite--comprise trematodiasis--and have and kill active compositions.Another object of the present invention provides a kind of suitable topical administration, particularly with the preparation method of closantel as the preparation of suspension.Also purpose of the present invention provides a kind of veterinary drug product that includes closantel and ivermectin in effective preparation, and the closantel bioavailability that has strengthened in this medicine is higher than the closantel bioavailability in the existing medicine.
Surprisingly, it is found that salicylamide optionally may be dissolved in one or more pure apoplexy due to endogenous wind with another kind of anthelmintic, and this preparation can use as suspension formulations, when in the skin that in predetermined a period of time, the suspension formulations part is applied to animal, in the blood of animal, will contain salicylamide and this another kind anthelmintic effectively.
Therefore, the invention provides a kind of effective suspension and kill parasite compositions, particularly compound products, wherein include closantel or class salicylamide, especially based on salicylamide and the another kind of binary preparation of killing parasite reagent, as avilamycin or arteries and veins heart type doubly, this is killed parasite reagent and has effective bioavailability.
Among the present invention, introduce polymer and can strengthen the effectiveness that suspension is killed the parasite compositions.A suitable polymer is Polyethylene Glycol (PEG) or polyvinylpyrrolidone (PVP), but other polymer also can use, as polyoxygenated ally alcohol/polyoxyethylene ether end-capped copolymer (poloxalkol, poloxamer).These polymeric chemical compounds also can reach expected result in the present invention.The content of these chemical compounds has nothing in common with each other, but maximum 35% (w/v) of minimum 0.1% (w/v) perhaps should have multiple polymer, and optimum content is 20% (w/v) in this case.
Considered among the present invention because polymer--as the existence of PEG--, increased the level that can be dissolved in the closantel in the suspension formulations.
According to a first aspect of the invention, salicylamide particularly closantel is present in the suspension formulations, it is characterized in that containing in drug-supplying system one or more alcohols of 20%v/v at least.Preferred alcohols is monohydroxy aliphatic or aromatic alcohols, and more preferably low alkanol (C1～C6).Contain the ethanol of 20%v/v at least in the most preferred drug-supplying system and in the preparation that uses, be added into the isopropyl alcohol of 100%v/v.
Usually, also comprise in the drug-supplying system of the present invention and be selected from Polyethylene Glycol (PEG), polyvinylpyrrolidone (PVP) and polyoxygenated ally alcohol/polyoxyethylene ether end-capped copolymer (poloxalkol, polymer poloxamer).When in drug-supplying system, containing PEG, PVP or poloxamer, so just extra active component is infiltrated into skin, thereby increased the total amount utilized of active medicine in the blood plasma of being treated main body for suspension formulations provides.
This drug-supplying system can adopt typical auxiliary agent to supply, as surfactant, bitterness denaturant (anti-licking), antiseptic, diffusion auxiliary agent or infraction reinforcing agent, and antioxidant etc., as butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA) (BHA) or sodium formaldehyde sulphoxylate.
According to a further aspect in the invention, a kind of killing contained the first parasite agent for killing that is selected from salicylamide in the parasitic compositions, and another kind is selected from the parasite agent for killing of avilamycin and Mei Bi mycin (Milbemycins), contains one or more alcohols of 20%v/v at least in its drug-supplying system.This drug-supplying system comprises first, second, tertiary or fragrant alcohols, preferred monohydric aliphatic alcohols or aromatic alcohol, more preferably low alkanol (C1～C6).Contain the ethanol of 20%v/v at least in the most preferred drug-supplying system and in the preparation that uses, be added into the isopropyl alcohol of 100%v/v.Typically, also comprise in the solution of the present invention and be selected from Polyethylene Glycol (PEG), polyvinylpyrrolidone (PVP) and polyoxygenated ally alcohol/polyoxyethylene ether end-capped copolymer (poloxalkol, polymer poloxamer).
Therefore, use alcohols, as independent use ethanol or with isopropyl alcohol and/or polymer such as PEG, PVP or poloxalkol (poloxamer) are used in combination, it is effective being considered to kill in the parasite compositions at the long-acting suspension that manufacturing contains closantel.Like this, polymeric consumption can make preparation have desired effect duration, thereby a controllable effective treatment phase is provided, thereby make those be butchered the animal of being treated that is used for the human consumption is arranged a withdrawal phase that meets the legal requirements.Polymer has been kept the dissolubility of closantel in drug-supplying system, particularly under the situation that has water to exist.In addition, the use of polymer such as PEG or PVP in the preparation of the present invention, the bioavailability that does not suppress avilamycin such as ivermectin, the suspension formulations that this explanation contains polymer such as PVP, poloxalkol (poloxamer) or PEG or its mixture can be used to effectively take the active component of different person's characters, and use widely may be arranged in the animal health field.
Contain in the suitable drug-supplying system and be selected from aliphatic or aromatic series alcohols as first, second, the solvent and the cosolvent of tertiary or fragrant alcohol.Preferred alcohols is monohydric aliphatic alcohols or aromatic alcohol, and more preferably low alkanol (C1～C6).Contain the ethanol of 20%v/v at least in the most preferred drug-supplying system and in the preparation that uses, be added into the isopropyl alcohol of 100%v/v.Preferably, a kind of alcohols wherein is to contain the ethanol of 20%v/v total amount at least, makes the solution total amount reach the isopropyl alcohol of 100%v/v during another kind of alcohol is to use.
Optionally, contain low alkanol such as ethanol in the drug-supplying system and such as the ethylene glycol solvent of PEG solvent, and to wherein adding isopropyl alcohol so that the solution total amount in using reaches 100%v/v.
According to the difference of molecular weight, a series of PEG solvent is that commerce can get.Can select PEG to exist or PEG is dissolved in any in the liquid effectively or PEG solvent that other can prepare uses with convenient with liquid form.Usually, the molecular weight of the PEG that commerce can get is between 200 to 6000, and these all can be used for purpose of the present invention, but PEG 200 to PEG 600 is more effective in the present invention.Preferred getting in the drug-supplying system contained solvent PEG 200 and ethanol and isopropyl alcohol, and (as PVP) comes together to strengthen permeability together with polymer.
A certain proportion of PVP can be replaced by high-molecular weight Polyethylene Glycol, and described molecular weight polyethylene glycol reaches as high as 20000.
Therefore according to the present invention, in single suspension formulations, obtain especially closantel of salicylamide, and avilamycin ivermectin especially, be possible, to the animal body dispenser time, just can effectively take closantel like this, thereby obtain the effective plasma level concentration of closantel and ivermectin simultaneously.Certainly, under the situation of clinical needs, also can contain a kind of in these active component in the preparation separately.
The possible component that is used for parasite agent for killing preparation is:
Closantel, total amount/volumn concentration (w/v) 1 to 30%, preferred 1 to 15%;
Ivermectin total amount/volumn concentration (w/v) 0.1 to 10%, preferred 0.1 to 5%;
The polymeric amount particularly necessary effective dose of PEG depends on needed salicylamide activity in the mixture, but preferred total amount/volumn concentration is at least 3%, is more preferably 20% higher as the required effective content that reaches of closantel to allow.Employed polymeric amount only is subjected to alcohols quantitative limitation in the drug-supplying system, its high-load can reach 80% (volume content, v/v).
Description of drawings
The invention will be further described below in conjunction with drawings and Examples, in the accompanying drawing:
Pharmacokinetics between preparation among the present invention of being shown in Figure 1 and the commercial product that can get is sketch map relatively.
The specific embodiment
Come the present invention is set forth below in conjunction with present known preferred example.
Formulation examples
For preparation is used for the binary joint product that suspension takes, the active component closantel that is provided and the total amount of ivermectin are the ivermectins that takes the closantel and 0.5% (w/v) of liquid 10% (w/v).The drug-supplying system that is adopted comprises solvent PEG 200, ethanol and isopropyl alcohol, and together with the permeability reinforcing agent, solvent wherein is to be convenient to supply with effective living solution.The formulation examples of several compositionss is as follows:
Preparation 1
Ivermectin 0.25%w/v
Closantel 5.0%w/v
Ethanol 30%v/v
Isopropyl alcohol complements to 100%v/v
Preparation 2
Ivermectin 0.5%w/v
Closantel (with sodium-salt form) 10.0%w/v
PVP 15.0％w/v
Ethanol 20%v/v
PEG200 20％v/v
Isopropyl alcohol complements to 100%v/v
Preparation 3
Ivermectin 0.5%w/v
Closantel 10.0%w/v
PVP 6.0％w/v
Sad cetearyl alcohol ester/isopropyl myristate (demulcent ester admixture) 10%w/v
Tributyl citrate 0.3%w/v
Macrogol 200 20%v/v
Ethanol 20%v/v
Peaceful (Denatonium benzoate) 0.05%w/v of benzoic acid degeneration holder
Isopropyl alcohol complements to 100%v/v
General formulation method
These preparations are to make by conventional industrial method as described below.
The dispenser example
Preparation recited above (1,2 and 3) is the medicine of using according to the industrial procedure of generally acknowledging, and is as follows to their method of testing.
The above-mentioned preparation compositions (preparation 1,2 and 3) that contains closantel and ivermectin is put on the cattle body with the ratio of dosage 500 micrograms/kg body weight of being equivalent to ivermectin and the ratio of closantel dosage 10 mg/kg body weight.
The result of closantel is shown in table 1,4 and 5 in the blood plasma, and the result of ivermectin is shown in table 2,3 and 6.
Table 1
After the suspension dispenser of dosage rate with the 10mg/kg body weight in a certain occasion with preparation 1
The blood plasma level of closantel (μ g/ml)
| Hour | The average of closantel | Standard deviation (SEM) |
| 24 | 2.0 | 1.21 |
| 48 | 10.3 | 3.57 |
| 60 | 14.44 | 4.75 |
| 72 | 18.18 | 5.6 |
| 80 | 19.63 | 6.01 |
| 96 | 21.57 | 6.46 |
| 120 | 22.10 | 6.53 |
| 168 | 24.98 | 7.28 |
| 240 | 26.96 | 7.53 |
After the suspension dispenser of dosage rate with 500 μ g/kg body weight in a certain occasion of table 2 with preparation 1
The blood plasma level (ng/ml) of ivermectin in the cattle body
| Hour | The average of closantel | Standard deviation (SEM) |
| 24 | 4.95 | 1.14 |
| 48 | 14.53 | 3.49 |
| 60 | 16.60 | 5.44 |
| 72 | 19.11 | 6.23 |
| 80 | 19.94 | 6.19 |
| 96 | 19.73 | 6.41 |
| 120 | 18.27 | 5.61 |
| 168 | 16.18 | 5.03 |
| 240 | 10.55 | 3.23 |
After the suspension dispenser of dosage rate with 500 μ g/kg body weight in a certain occasion of table 3 with preparation 2
The blood plasma level (ng/ml) of ivermectin in the cattle body
| Hour | Average | Standard deviation (SEM) |
| 24 | 19.19 | 14.91 |
| 48 | 19.45 | 12.56 |
| 72 | 13.84 | 6.82 |
| 96 | 11.98 | 5.32 |
| 120 | 9.48 | 3.79 |
| 144 | 7.77 | 3.28 |
| 168 | 6.38 | 2.47 |
| 192 | 4.96 | 2.02 |
| 216 | 3.97 | 1.31 |
| 240 | 3.95 | 1.22 |
| 264 | 3.22 | 1.07 |
After the suspension dispenser of dosage rate with the 10mg/kg body weight in a certain occasion of table 4 with preparation 2
The blood plasma level of closantel (μ g/ml)
| Hour | Average | Standard deviation (SEM) |
| 24 | 5.45 | 1.65 |
| 48 | 40.80 | 22.31 |
| 72 | 48.60 | 25.01 |
| 96 | 49.03 | 24.07 |
| 120 | 49.27 | 22.88 |
| 144 | 47.07 | 23.36 |
| 168 | 46.53 | 21.77 |
| 192 | 51.47 | 27.06 |
| 216 | 50.43 | 29.37 |
| 240 | 50.17 | 26.79 |
| 264 | 25.85 | 11.06 |
Table 5
After the suspension dispenser of dosage rate with the 10mg/kg body weight in a certain occasion with preparation 3
The blood plasma level of closantel (μ g/ml)
| Hour | Average | Standard deviation (SEM) |
| 24 | 36.2 | 12.2 |
| 48 | 42.8 | 23.4 |
| 54 | 43.8 | 23.6 |
| 72 | 52.2 | 29 |
| 78 | 55.6 | 30.2 |
| 96 | 47.2 | 24.6 |
| 120 | 45.4 | 22.6 |
| 192 | 39 | 20.2 |
| 240 | 34.6 | 10.4 |
Table 6
After the suspension dispenser of dosage rate with 500 μ g/kg body weight in a certain occasion with preparation 3
The blood plasma level (ng/ml) of ivermectin in the cattle body
| Hour | Average | Standard deviation (SEM) |
| 24 | 15.64 | 4.54 |
| 48 | 28.76 | 8.84 |
| 54 | 25.40 | 6.70 |
| 72 | 19.79 | 4.68 |
| 78 | 17.89 | 4.07 |
| 96 | 15.25 | 3.90 |
| 120 | 12.75 | 1.59 |
| 192 | 7.88 | 1.43 |
| 240 | 6.22 | 1.21 |
By table 2,3 and 6 as seen, the level of ivermectin is suitable for cattle is treated in the blood plasma, because the level of this ivermectin is similar to the level that adopts the commercial product of buying (only containing ivermectin).
By table 1,4 and 5 as can be known, the closantel level of gained has reached the level of desired clinical effective product, and its plasma concentration is most important to the schistosomacidal usefulness of product clinically.The plasma concentration that bilharzial activity is based on flukicide---aged acceleration can be eliminated reduction because plasma concentration is to the trematodiasis maturation, thereby has increased the probability of curing fully in well-known successful killing.According to the plasma concentration of closantel in the table 1,4 and 5 can guess in promise Brooker (Norbrook) invention preparation to grow up with minor trematodiasis all be effective.
Resulting closantel result also is significantly higher than the record among the WO 97/13508, and the maximal plasma concentration that 10mg/kg closantel local dose ratio obtains in WO97/13508 only is 8.37ug/ml (in 10 days).In order to reach the plasma concentration level of 52.97mg/kg, need apply the dosage of 40mg/kg in the said preparation.In the accompanying drawings the dosage of 10mg/kg in the document and the result in the table 2 are compared.Can find out significantly, have very big advantage aspect the pharmacokinetics of preparation during maximal plasma concentration and activity that the Norbrook invention is provided, this product that shows that the Norbrook invention is provided has better clinical efficacy in tackling the trematodiasis in each stage.For reaching same effect, the dosage that scheme among the WO 97/13508 need apply is 40mg/kg---this is very high dosage concerning closantel, will bring toxic excessive risk thereby is vetoed on the pharmacokinetics aspect animal for reaching needed blood plasma level.This shows that compositions provided by the invention has unexpected advantage than prior art.
Commercial Application
Consider above-mentioned advantage and the characteristic of composition described herein, the present invention can effectively be applied to the animal doctor field, in particular for tackling endoparasite and ectoparsite to alleviate the misery of the domestic animals such as ox, horse, sheep, goat.
Claims (19)
1, a kind of antiparasitic suspension composite is characterized in that comprising in its drug-supplying system one or more alcohols of volumn concentration at least 20% and the salicylamide anti-parasitic chemical compound of effective dose.
2, antiparasitic composition according to claim 1 is characterized in that, wherein also comprises at least a other anti-parasitic chemical compound of effective dose.
3, compositions according to claim 1 is characterized in that, salicylamide wherein is the chlorocyaniosaliamine amine salt of approving on closantel or the materia medica.
According to claim 2 or 3 described compositionss, it is characterized in that 4, another kind of anti-parasitic chemical compound wherein is to be selected from U.S.A to compare mycin.
5, compositions according to claim 2 is characterized in that, another kind of anti-parasitic chemical compound wherein is to be selected from avilamycin.
6, compositions according to claim 5 is characterized in that, avilamycin chemical compound wherein is an ivermectin.
7, compositions according to claim 6 is characterized in that, wherein the weight/volume content of ivermectin is 0.1 to 10%.
According to claim 2 or 3 described compositionss, it is characterized in that 8, wherein the weight/volume content of closantel is 1 to 30%.
9, compositions according to claim 1 is characterized in that, the alcohols that contains in the drug-supplying system wherein is to be selected from primary, deputy and the 3rd aliphatic alcohol.
10, compositions according to claim 1 is characterized in that, the alcohols that contains in the drug-supplying system wherein is to be selected from aromatic alcohols.
11, compositions according to claim 1 is characterized in that, the alcohols that contains in the drug-supplying system wherein is the low alkanol that is selected from C1～C6.
12, compositions according to claim 1 is characterized in that, contains the ethanol of Polyethylene Glycol, isopropyl alcohol and at least 20% in the drug-supplying system wherein.
13, compositions according to claim 1 is characterized in that, contains the polymer that one or more are selected from Polyethylene Glycol, polyvinylpyrrolidone and poloxalkol in the drug-supplying system wherein.
14, compositions according to claim 13 is characterized in that, wherein polymeric weight/volume content is 0.1 to 80%.
15, compositions according to claim 13 is characterized in that, wherein polymeric weight/volume content is 3 to 20%.
16, compositions according to claim 13 is characterized in that, polymer wherein is a polyvinylpyrrolidone.
17, compositions according to claim 1, it is characterized in that, also comprise at least a following additive in the drug-supplying system wherein: surfactant, bitterness denaturant (anti-licking), antiseptic, diffusion auxiliary agent, infiltration or infraction reinforcing agent, and antioxidant.
18, the described compositions of claim 1 is applied to eradicate marita and teenage trematodiasis.
19, a kind of compositions described in formulation examples above.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0316377.1 | 2003-07-12 | ||
| GBGB0316377.1A GB0316377D0 (en) | 2003-07-12 | 2003-07-12 | Parasiticidal composition |
| PCT/GB2004/003006 WO2005007241A1 (en) | 2003-07-12 | 2004-07-12 | Parasiticidal composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1822880A true CN1822880A (en) | 2006-08-23 |
| CN1822880B CN1822880B (en) | 2012-07-11 |
Family
ID=27742085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200480020006XA Expired - Fee Related CN1822880B (en) | 2003-07-12 | 2004-07-12 | Parasiticidal composition |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8993546B2 (en) |
| EP (2) | EP2286876A1 (en) |
| JP (1) | JP4677405B2 (en) |
| KR (1) | KR101095419B1 (en) |
| CN (1) | CN1822880B (en) |
| AP (1) | AP2956A (en) |
| AU (1) | AU2004257450B2 (en) |
| BR (1) | BRPI0412522A (en) |
| CA (1) | CA2532199C (en) |
| CR (1) | CR8174A (en) |
| DK (1) | DK1646425T3 (en) |
| EA (1) | EA009602B1 (en) |
| EC (1) | ECSP066360A (en) |
| ES (1) | ES2390224T3 (en) |
| GB (2) | GB0316377D0 (en) |
| GE (1) | GEP20094648B (en) |
| HK (1) | HK1096621A1 (en) |
| HR (1) | HRP20120721T1 (en) |
| IL (1) | IL173057A (en) |
| MX (1) | MXPA06000135A (en) |
| NO (1) | NO336181B1 (en) |
| NZ (1) | NZ544973A (en) |
| OA (1) | OA13188A (en) |
| PL (1) | PL1646425T3 (en) |
| PT (1) | PT1646425E (en) |
| SI (1) | SI1646425T1 (en) |
| TN (1) | TNSN06006A1 (en) |
| WO (1) | WO2005007241A1 (en) |
| ZA (1) | ZA200600374B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101693009B (en) * | 2009-10-27 | 2010-12-01 | 纽素乐必佳（天津）药业集团有限公司 | Antiparasitic closantel sodium transdermal solution for ox and sheep and preparation method thereof |
| CN113242747A (en) * | 2018-10-12 | 2021-08-10 | 好利安科技有限公司 | Macrolide formulations, method for preparing them and use of said formulations in the treatment of diseases secondary to ocular parasites |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002952597A0 (en) * | 2002-11-11 | 2002-11-28 | Schering-Plough Pty. Limited | Topical parasiticide formulations and methods of treatment |
| GB0501220D0 (en) * | 2005-01-21 | 2005-03-02 | Norbrook Lab Ltd | Anthelmintic composition |
| GB0711957D0 (en) * | 2007-06-21 | 2007-08-01 | Syntopix Ltd | Formulations |
| FR2991173B1 (en) | 2012-06-04 | 2015-11-06 | Virbac | VETERINARY COMPOSITION WITH OXYCLOZANIDE BASED SKIN ADMINISTRATION |
| CN103720652B (en) * | 2014-01-07 | 2016-09-28 | 王玉万 | Prepare containing Avermectins medicine injection with poloxamer and oil medium |
| WO2019054967A2 (en) * | 2017-03-15 | 2019-03-21 | Verano Ilac Sanayi Ve Ticaret Anonim Sirketi | A pour on veterinary composition comprising eprinomectin |
| GB201715122D0 (en) * | 2017-09-19 | 2017-11-01 | Omnipharm Dev Ltd | Topical anti-infective formulation |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2731386A (en) * | 1951-09-06 | 1956-01-17 | Wallace & Tiernan Company Inc | Antifungal composition |
| US3798258A (en) * | 1970-03-13 | 1974-03-19 | Merck & Co Inc | Salicylanilides |
| LU62350A1 (en) * | 1970-12-31 | 1972-08-23 | ||
| US3950360A (en) | 1972-06-08 | 1976-04-13 | Sankyo Company Limited | Antibiotic substances |
| US4005218A (en) | 1975-03-18 | 1977-01-25 | Janssen Pharmaceutica N.V. | Antiparasitic salicylanilide derivatives |
| SE434277B (en) | 1976-04-19 | 1984-07-16 | Merck & Co Inc | SET TO MAKE NEW ANTIHELMINTICALLY EFFECTIVE ASSOCIATIONS BY CULTIVATING STREPTOMYCS AVERMITILIS |
| US4199569A (en) | 1977-10-03 | 1980-04-22 | Merck & Co., Inc. | Selective hydrogenation products of C-076 compounds and derivatives thereof |
| US4201861A (en) | 1977-10-03 | 1980-05-06 | Merck & Co., Inc. | Acyl derivatives of C-076 compounds |
| US4206205A (en) | 1977-10-03 | 1980-06-03 | Merck & Co., Inc. | Monosaccharide and aglycone derivatives of C-076 |
| US4171314A (en) | 1977-12-19 | 1979-10-16 | Merck & Co., Inc. | 13-Halo and 13-deoxy C-076 compounds |
| US4173571A (en) | 1977-12-19 | 1979-11-06 | Merck & Co., Inc. | 13-Halo and 13-deoxy derivatives of C-076 compounds |
| NZ197796A (en) | 1980-08-04 | 1984-11-09 | Merck & Co Inc | Stabilised aqueous formulations containing ivermectin |
| NZ210505A (en) | 1983-12-22 | 1988-06-30 | Merck & Co Inc | Parasiticidal compositions containing avermectin or milbemycin derivatives |
| NZ335166A (en) | 1999-04-14 | 2001-11-30 | Ashmont Holdings Ltd | Anthelmintic composition containing triclabendazole in at least one solvent |
| RU2033150C1 (en) | 1992-06-10 | 1995-04-20 | Виктор Антонович Дриняев | Preparation for treatment and prophylaxis of psoroptosis in animals |
| PL174488B1 (en) * | 1993-05-10 | 1998-08-31 | Merck & Co Inc | Preparations for fighting against animal parasites and method of obtaining such preparations |
| EP0705101B1 (en) * | 1993-05-26 | 2001-12-19 | Commonwealth Scientific And Industrial Research Organisation | Antiparasitic compositions |
| WO1994028887A1 (en) | 1993-06-15 | 1994-12-22 | The Australian National University | Synergistic anthelmintic compositions |
| NZ248486A (en) * | 1993-08-24 | 1996-07-26 | Ashmont Holdings Limited Subst | Stable anthelmintic formulation containing closantel and one or more avermectins or milbemycins in a glycol based solvent |
| FR2739778B1 (en) * | 1995-10-13 | 1997-12-12 | Virbac Lab | TOPICAL FORMULATION FOR TREATING LIVER DISEASE DISEASE IN ANIMALS |
| RU2112508C1 (en) | 1995-12-26 | 1998-06-10 | Писков Вячеслав Борисович | Method of treatment and prophylaxis of sarcoptoidosis in animals |
| RU2121831C1 (en) | 1997-08-01 | 1998-11-20 | Анатолий Александрович Непоклонов | Preparation for prophylaxis and treatment of cattle with hypodermatosis |
| AUPP105497A0 (en) * | 1997-12-19 | 1998-01-15 | Schering-Plough Animal Health Limited | Aqueous insecticidal pour-on treatment |
| RU2129430C1 (en) | 1998-03-17 | 1999-04-27 | Общество С Ограниченной Ответственностью "Вик - Здоровье Животных" | Preparation "santomectin" for ecto- and endoparasites control in animals |
| US6239119B1 (en) * | 1998-04-27 | 2001-05-29 | Medimmune Oncology, Inc. | Topical administration of amifostine and related compounds |
| GB9816132D0 (en) * | 1998-07-24 | 1998-09-23 | Norbrook Lab Ltd | Non-aqueous anthelmintic composition |
| GEP20012490B (en) | 1999-10-21 | 2001-07-25 | Robizon Bostashvili | Means Against Demodicosis of Agricultural and Domestic Animals |
| US6340672B1 (en) * | 2000-02-16 | 2002-01-22 | Phoenix Scientific, Inc. | Parasiticidal formulation and a method of making this formulation |
| US6399651B1 (en) * | 2000-06-29 | 2002-06-04 | L. Dean Parks | Method of treating dermatoses using avermectin compound |
| AUPQ875700A0 (en) * | 2000-07-13 | 2000-08-03 | Reflex Research Limited | Combination compositions |
| US7238680B2 (en) * | 2001-06-01 | 2007-07-03 | Rosen Steven E | Topical compositions for veterinary uses |
| GB2386067A (en) * | 2002-02-28 | 2003-09-10 | Norbrook Lab Ltd | Long-acting parasiticidal composition with improved bioavailability comprising an avermectin or milbemycin, plus a salicylanilide & a polymeric species |
| AU2003275779B2 (en) * | 2002-11-11 | 2009-02-05 | Schering-Plough Pty. Limited | Topical parasiticide formulations and methods of treatment |
| AU2002952597A0 (en) * | 2002-11-11 | 2002-11-28 | Schering-Plough Pty. Limited | Topical parasiticide formulations and methods of treatment |
| AU2003900505A0 (en) * | 2003-02-05 | 2003-02-20 | Jurox Pty Ltd | Anthelmintic composition |
-
2003
- 2003-07-12 GB GBGB0316377.1A patent/GB0316377D0/en not_active Ceased
-
2004
- 2004-07-12 ES ES04743347T patent/ES2390224T3/en active Active
- 2004-07-12 AU AU2004257450A patent/AU2004257450B2/en active Active
- 2004-07-12 CA CA2532199A patent/CA2532199C/en not_active Expired - Fee Related
- 2004-07-12 PT PT04743347T patent/PT1646425E/en unknown
- 2004-07-12 GB GB0415541A patent/GB2403905B/en active Active
- 2004-07-12 BR BRPI0412522-3A patent/BRPI0412522A/en not_active IP Right Cessation
- 2004-07-12 AP AP2006003506A patent/AP2956A/en active
- 2004-07-12 EP EP10012261A patent/EP2286876A1/en not_active Withdrawn
- 2004-07-12 OA OA1200600008A patent/OA13188A/en unknown
- 2004-07-12 EP EP04743347A patent/EP1646425B1/en active Active
- 2004-07-12 EA EA200600237A patent/EA009602B1/en not_active IP Right Cessation
- 2004-07-12 DK DK04743347.9T patent/DK1646425T3/en active
- 2004-07-12 SI SI200431947T patent/SI1646425T1/en unknown
- 2004-07-12 MX MXPA06000135A patent/MXPA06000135A/en active IP Right Grant
- 2004-07-12 CN CN200480020006XA patent/CN1822880B/en not_active Expired - Fee Related
- 2004-07-12 JP JP2006519991A patent/JP4677405B2/en active Active
- 2004-07-12 NZ NZ544973A patent/NZ544973A/en unknown
- 2004-07-12 PL PL04743347T patent/PL1646425T3/en unknown
- 2004-07-12 WO PCT/GB2004/003006 patent/WO2005007241A1/en active Application Filing
- 2004-07-12 GE GEAP20049216A patent/GEP20094648B/en unknown
- 2004-07-12 KR KR1020067000779A patent/KR101095419B1/en not_active IP Right Cessation
-
2006
- 2006-01-05 CR CR8174A patent/CR8174A/en unknown
- 2006-01-09 TN TNP2006000006A patent/TNSN06006A1/en unknown
- 2006-01-10 IL IL173057A patent/IL173057A/en not_active IP Right Cessation
- 2006-01-12 US US11/330,671 patent/US8993546B2/en active Active
- 2006-01-13 ZA ZA200600374A patent/ZA200600374B/en unknown
- 2006-02-10 EC EC2006006360A patent/ECSP066360A/en unknown
- 2006-02-10 NO NO20060676A patent/NO336181B1/en not_active IP Right Cessation
-
2007
- 2007-02-09 HK HK07101577.2A patent/HK1096621A1/en not_active IP Right Cessation
-
2012
- 2012-09-10 HR HRP20120721TT patent/HRP20120721T1/en unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101693009B (en) * | 2009-10-27 | 2010-12-01 | 纽素乐必佳（天津）药业集团有限公司 | Antiparasitic closantel sodium transdermal solution for ox and sheep and preparation method thereof |
| CN113242747A (en) * | 2018-10-12 | 2021-08-10 | 好利安科技有限公司 | Macrolide formulations, method for preparing them and use of said formulations in the treatment of diseases secondary to ocular parasites |
| CN113242747B (en) * | 2018-10-12 | 2023-09-08 | 好利安科技有限公司 | Macrolide formulations, methods of preparation and use of said formulations in the treatment of diseases secondary to ocular parasites |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4480400B2 (en) | Persistent anthelmintic composition comprising a salicylanilide compound, a polymer component and at least one other antiparasitic compound | |
| US20060142216A1 (en) | Parasiticidal composition | |
| TW200423871A (en) | Topical parasiticide formulations and methods of treatment | |
| KR20080073700A (en) | Benzimidazole non-aqueous compositions | |
| KR20100020003A (en) | Stable non-aqueous pour-on compositions | |
| CN107157995B (en) | A kind of compound imidacloprid transdermal composition preparation of pet broad-spectrum anti-parasite | |
| EP1940396B1 (en) | Anthelmintic formulations | |
| JP6273252B2 (en) | Long-acting composition | |
| NZ608177A (en) | Long acting compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1096621 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1096621 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120711 Termination date: 20140712 |
|
| EXPY | Termination of patent right or utility model |